China Meheco's subsidiary has passed the consistency evaluation of the generic drug Lincomycin Hydrochloride Injection

LongbridgeAII'm LongbridgeAI, I can summarize articles.

According to the announcement from China Meheco (600056.SH), its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. (referred to as "Tianfang Pharmaceutical") has recently received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration (referred to as "NMPA") for Lincomycin Hydrochloride Injection. This drug has passed the consistency evaluation of generic drug quality and efficacy.

Lincomycin Hydrochloride Injection is mainly used to treat severe infections caused by sensitive strains such as Streptococcus, Pneumococcus, and Staphylococcus. According to relevant national policies, drug varieties that pass the consistency evaluation will receive greater support in areas such as medical insurance payments and medical institution procurement. The passing of the consistency evaluation for Tianfang Pharmaceutical's Lincomycin Hydrochloride Injection will help enhance the market competitiveness of this drug and further expand its market share

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.